Loading…
← CockpitCompetitor Analysis › PLSE Pulse Biosciences, Inc.Open in the cockpit ↗

Pulse Biosciences, Inc.PLSECompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Medical device company developing Nano-Pulse Stimulation technology for non-thermal tissue ablation in dermatology and oncology.

Momentum leader 89
Mkt cap
$3.37B
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$22.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.3%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$45.83
1D+2.2%
1W-19.6%
1M-9.8%
3M-4.2%
6M+75.7%
YTD+233.8%
1Y+233.3%
ATR %8.9%
Beta2.21
52w lowhigh22.2% off high

What Pulse Biosciences does

Medical device company developing Nano-Pulse Stimulation technology for non-thermal tissue ablation in dermatology and oncology.

Sells very little: the dermatology system, CellFX, was a small commercial effort, and effort has since been redirected toward cardiac ablation devices. Spending is funded by investors and loans, with chairman and major shareholder Robert Duggan the main backer.

Products and services

  • CellFX System (dermatology)
  • Nano-Pulse Stimulation (NPS) technology
  • Oncology/cardiac ablation research

Customers

  • Dermatologists
  • Medical aesthetics practices

Where it sits in the supply chain

  • Medical devices
  • Energy-based tissue ablation
  • Non-thermal cell-ablation technology

What could go right

  • Dermatology/aesthetics adoption growth
  • Oncology ablation pipeline

What could go wrong

  • Early commercial-stage revenue risk
  • Capital-intensive device adoption cycle

Moat: narrow (IP / patents). Patented Nano-Pulse Stimulation technology offers a non-thermal ablation approach distinct from laser/RF competitors.

Headquarters: Hayward, California · Founded: 2014 · Employees: 116

Named competitors

Pulse Biosciences at a glance

Size Pulse Biosciences (PLSE) is a United States Health Care company (Medical Specialties) with a market value of $3.37B, the 1460th largest of 3,085 United States companies the cockpit tracks. Shares closed at $45.83 on 18 Nov 2026.

Performance Over six months the shares gained 75.7%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 1,637.2% over the last twelve months (peer median +5.7%); the operating margin is -5,821.1% (peer median 8.3%).

Valuation It trades at 2,133.8× enterprise value to sales against a peer median of 4.7× (most expensive of 21).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026PLSE 179Peer median 104
Six months, rebased to 100: Pulse Biosciences against the median of its 20 peers (local-currency closes).

Pulse Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.49M$350,000$0$0$700,000
Revenue growth———-100%—
Gross profit$10,500-$1.26M-$1.18M-$1.21M-$12.6M
EBITDA-$85.9M-$75.9M-$53.2M-$42.4M-$56.7M
Net income-$83.7M-$72.8M-$53.6M-$42.2M-$58.5M
Free cash flow-$63.7M-$54.4M-$36.5M-$33.2M-$47.4M
Capital expenditure$370,000$335,000$125,000$121,000$401,000
Total debt$6.36M$7.53M$8.90M$9.14M$76.0M

Quarterly statements and history in the cockpit →

Pulse Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%603658TMDXAXGN688301AMBU-B6033014203300003IRTCAFXTECN6030146881141SXPNVST002432CDNAFIEATRCCOTNPLSE6-month return →1-month return →
Up and to the right = strong over both horizons. Pulse Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×1,000×2,000×603658TMDXPLSERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pulse Biosciences is the large dot.

Pulse Biosciences competitors and peer comparison

Head to head with its named competitors (PLSE vs INMD vs BSX vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Pulse Biosciences PLSE$3.37B+76%+1,637%-5,821%2,133.8×n/a
InMode INMD$741M-8%+2%18%0.6×-10.8%
Boston Scientific BSX$63.3B-23%+9%21%3.5×5.8%
Medtronic MDT$129B+30%+10%20%4.0×9.1%

How Pulse Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pulse Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasurePLSEPeer medianRank in peer set
1-month return-9.8%+3.0%6th lowest of 21
6-month return+75.7%+3.2%3rd highest of 21
Distance from 52-week high-22.2%-24.0%11th highest of 21
Revenue growth (TTM)+1,637.2%+5.7%highest of 21
Operating margin-5,821.1%8.3%lowest of 20
EV / Sales2,133.8×4.7×most expensive of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%2,133.8×n/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%5.0×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%5.1×38.4%+88.2%
Axogen AXGNUnited States$3.40B+33%+24%-5%11.5×52.6%+14.9%
iRay Technology 688301.SSChina$3.31B-30%+58%24%6.9×n/an/a
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%3.7×10.0%+10.0%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%4.8×22.9%-16.1%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%1.2×8.6%+8.9%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%4.1×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%3.9×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%1.6×12.5%+10.8%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%3.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a4.8×-1.2%+8.1%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%5.9×43.7%-0.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%3.3×12.7%+11.0%
Envista NVSTUnited States$3.81B0%+10%12%1.5×4.8%+7.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%23.6×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%7.4×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%1.7×-5.5%+11.3%
AtriCure ATRCUnited States$2.82B+91%+14%3%4.6×54.2%+20.9%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%5.0×n/an/a

Questions

Who are Pulse Biosciences's main competitors?
Named competitors: Cutera (private or unlisted), InMode (INMD), Boston Scientific (BSX), Medtronic (MDT), Venus Concept (private or unlisted), Sisram Medical (private or unlisted). The cockpit's measured peer set (industry) also includes Autobio Diagnostics (603658.SS), TransMedics (TMDX), Axogen (AXGN), iRay Technology (688301.SS), Ambu A/S (AMBU-B.CO), Zhende Medical (603301.SS).
Is Pulse Biosciences expensive compared with its peers?
On ev / sales it trades at 2,133.8× against a peer median of 4.7×, most expensive of 21 in its peer set.
How has Pulse Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +75.7% against +3.2% for the median peer; over one year +233.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.